Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants.

ABSTRACT: Essentials Currently, DOACs are given at fixed doses and do not require laboratory monitoring. Direct oral anticoagulant-specific measurements were performed at trough and peak. Patients who developed bleeding events showed higher DOAC plasma levels at peak. This study suggests the need of a more accurate DOAC dose assessment.

Background

Direct oral anticoagulants (DOACs) are administered at fixed dose. The aim of the study was to evaluate the relationship between DOAC C-trough or C-peak plasma levels and bleeding complications in patients with non-valvular atrial fibrillation (NVAF).

Methods

Five hundred sixty five consecutive naive NVAF patients were enrolled. The DOAC measurements at C-trough and at C-peak (available in 411 patients) were performed at steady state, within

SUBMITTER: Testa S 

PROVIDER: S-EPMC6852698 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature